Published in Hypertension on February 16, 2004
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology (2006) 2.26
The pathogenesis of cardiac fibrosis. Cell Mol Life Sci (2013) 1.96
The chemokine monocyte chemoattractant protein-1 contributes to renal dysfunction in swine renovascular hypertension. J Hypertens (2009) 1.88
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation (2015) 1.55
From inflammation to fibrosis: a stiff stretch of highway. Hypertension (2004) 1.54
Serum albumin concentration and heart failure risk The Health, Aging, and Body Composition Study. Am Heart J (2010) 1.54
Characterization of the inflammatory and fibrotic response in a mouse model of cardiac pressure overload. Histochem Cell Biol (2008) 1.45
Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol (2005) 1.30
NADPH oxidases in heart failure: poachers or gamekeepers? Antioxid Redox Signal (2012) 1.27
Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension (2010) 1.20
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br J Pharmacol (2010) 1.16
Interstitial myocardial fibrosis in a captive chimpanzee (Pan troglodytes) population. Comp Med (2008) 1.14
Dynamic molecular and histopathological changes in the extracellular matrix and inflammation in the transition to heart failure in isolated volume overload. Am J Physiol Heart Circ Physiol (2011) 1.07
Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) (2009) 1.03
Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling. Int J Inflam (2011) 1.02
Cardiac 12/15 lipoxygenase-induced inflammation is involved in heart failure. J Exp Med (2009) 1.01
Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation (2015) 0.96
Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target. Heart Fail Rev (2014) 0.95
Mast cells and metabolic syndrome. Biochim Biophys Acta (2010) 0.95
How can we cure a heart "in flame"? A translational view on inflammation in heart failure. Basic Res Cardiol (2013) 0.94
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
Monocyte and macrophage contributions to cardiac remodeling. J Mol Cell Cardiol (2015) 0.93
Monocyte chemoattractant proteins mediate myocardial microvascular dysfunction in swine renovascular hypertension. Arterioscler Thromb Vasc Biol (2009) 0.92
Calpain activity is essential in skin wound healing and contributes to scar formation. PLoS One (2012) 0.92
The effect of an Angiotensin receptor blocker on arterial stiffness in type 2 diabetes mellitus patients with hypertension. Diabetes Metab J (2011) 0.89
18-HEPE, an n-3 fatty acid metabolite released by macrophages, prevents pressure overload-induced maladaptive cardiac remodeling. J Exp Med (2014) 0.87
IκBβ attenuates angiotensin II-induced cardiovascular inflammation and fibrosis in mice. Hypertension (2011) 0.86
Beneficial effects of long-term administration of an oral formulation of Angiotensin-(1-7) in infarcted rats. Int J Hypertens (2012) 0.85
Molecular determinants of the cardiometabolic phenotype. Endocr Metab Immune Disord Drug Targets (2010) 0.84
Coronary artery remodeling in a model of left ventricular pressure overload is influenced by platelets and inflammatory cells. PLoS One (2012) 0.83
Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis. Fibrogenesis Tissue Repair (2012) 0.83
Blockade of glucocorticoid receptors with RU486 attenuates cardiac damage and adipose tissue inflammation in a rat model of metabolic syndrome. Hypertens Res (2015) 0.83
Deletion of phd2 in myeloid lineage attenuates hypertensive cardiovascular remodeling. J Am Heart Assoc (2013) 0.83
Atrial natriuretic peptide exerts protective action against angiotensin II-induced cardiac remodeling by attenuating inflammation via endothelin-1/endothelin receptor A cascade. Heart Vessels (2013) 0.82
Effects of interleukin-33 on cardiac fibroblast gene expression and activity. Cytokine (2012) 0.82
Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One (2014) 0.81
Could interferon-gamma be a therapeutic target for treating heart failure? Heart Fail Rev (2014) 0.81
Cardiomyocyte-specific inactivation of thyroid hormone in pathologic ventricular hypertrophy: an adaptative response or part of the problem? Heart Fail Rev (2010) 0.81
Protease-activated receptor 1 inhibition by SCH79797 attenuates left ventricular remodeling and profibrotic activities of cardiac fibroblasts. J Cardiovasc Pharmacol Ther (2013) 0.80
Roles of oxidative stress and the mineralocorticoid receptor in cardiac pathology in a rat model of metabolic syndrome. Nagoya J Med Sci (2015) 0.79
Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes. PLoS One (2012) 0.79
Estrogen modulates the influence of cardiac inflammatory cells on function of cardiac fibroblasts. J Inflamm Res (2013) 0.78
Association of micro albuminuria with diastolic function in obese normotensive no diabetic individuals. Nephrourol Mon (2014) 0.78
Advances in the pharmacotherapy of chronic heart failure with preserved ejection fraction: an ideal opportunity for precision medicine. Expert Opin Pharmacother (2017) 0.78
Time course of cardiac inflammation during nitric oxide synthase inhibition in SHR: impact of prior transient ACE inhibition. Hypertens Res (2015) 0.77
Molecular mechanism of aggravation of hypertensive organ damages by short-term blood pressure variability. Curr Hypertens Rev (2014) 0.76
Effects of sex and hypertension subtype on haemodynamics and left ventricular diastolic function in older patients with stage 1 hypertension. J Hypertens (2013) 0.76
Tetrahydrobiopterin Protects Against Hypertrophic Heart Disease Independent of Myocardial Nitric Oxide Synthase Coupling. J Am Heart Assoc (2016) 0.76
Premature cardiac senescence in DahlS.Z-Lepr(fa)/Lepr(fa) rats as a new animal model of metabolic syndrome. Nagoya J Med Sci (2014) 0.76
Selective gene expression analysis of muscular and vascular components in hearts using laser microdissection method. Int J Vasc Med (2012) 0.76
High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease. Open Cardiovasc Med J (2011) 0.75
Kinetic mRNA Profiling in a Rat Model of Left-Ventricular Hypertrophy Reveals Early Expression of Chemokines and Their Receptors. PLoS One (2016) 0.75
Protective effects of intercalated disk protein afadin on chronic pressure overload-induced myocardial damage. Sci Rep (2017) 0.75
The Role of Estrogen in Cardiac Metabolism and Diastolic Function. Methodist Debakey Cardiovasc J (2017) 0.75
Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems. Mediators Inflamm (2016) 0.75
Active components from Radix Scrophulariae inhibits the ventricular remodeling induced by hypertension in rats. Springerplus (2016) 0.75
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest (2006) 12.32
Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet (2002) 7.11
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res (2009) 5.24
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res (2014) 4.83
DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med (2005) 4.02
Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol (2006) 3.43
Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation (2002) 3.20
Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation (2002) 2.95
Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res (2007) 2.87
Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling. Hypertension (2004) 2.69
Higher heart rate may predispose to obesity and diabetes mellitus: 20-year prospective study in a general population. Am J Hypertens (2008) 2.54
Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension (2010) 2.37
Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol (2002) 2.26
Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res (2003) 2.26
A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol (2012) 2.23
Surgical outcome in 90 patients with craniopharyngioma: an evaluation of transsphenoidal surgery. World Neurosurg (2011) 2.17
Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol (2005) 2.09
Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des (2005) 2.06
The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol (2003) 2.03
Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta. JACC Cardiovasc Imaging (2011) 2.00
Blockade of CCR2 ameliorates progressive fibrosis in kidney. Am J Pathol (2004) 1.97
Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation (2004) 1.96
Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol (2002) 1.93
Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation (2003) 1.92
Mutations in prokineticin 2 and prokineticin receptor 2 genes in human gonadotrophin-releasing hormone deficiency: molecular genetics and clinical spectrum. J Clin Endocrinol Metab (2008) 1.92
Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.86
The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization. J Leukoc Biol (2003) 1.84
Apoptosis induced by inhibition of cyclic AMP response element-binding protein in vascular smooth muscle cells. Circulation (2003) 1.81
Gene therapy expressing amino-terminal truncated monocyte chemoattractant protein-1 prevents renal ischemia-reperfusion injury. J Am Soc Nephrol (2003) 1.80
Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest (2003) 1.79
Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. Am J Respir Crit Care Med (2007) 1.79
Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation (2003) 1.79
Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction. Am J Pathol (2004) 1.79
Overexpression of mitochondrial transcription factor a ameliorates mitochondrial deficiencies and cardiac failure after myocardial infarction. Circulation (2005) 1.75
Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol (2003) 1.74
High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism. Diabetes (2010) 1.74
CCR2 signaling contributes to ischemia-reperfusion injury in kidney. J Am Soc Nephrol (2003) 1.73
Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res (2006) 1.70
Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J (2008) 1.70
Titin mutations as the molecular basis for dilated cardiomyopathy. Biochem Biophys Res Commun (2002) 1.70
Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res (2007) 1.70
Bone marrow-derived monocyte chemoattractant protein-1 receptor CCR2 is critical in angiotensin II-induced acceleration of atherosclerosis and aneurysm formation in hypercholesterolemic mice. Arterioscler Thromb Vasc Biol (2004) 1.70
Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int (2009) 1.68
Mechanisms for atrial fibrillation in patients with Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2002) 1.67
Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. Kidney Int (2012) 1.62
Angiogenesis and vasculogenesis are impaired in the precocious-aging klotho mouse. Circulation (2004) 1.61
Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat Med (2005) 1.61
Coronary microvascular spasm causes myocardial ischemia in patients with vasospastic angina. J Am Coll Cardiol (2002) 1.61
Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol (2007) 1.60
Ultrasound stimulation restores impaired neovascularization-related capacities of human circulating angiogenic cells. Cardiovasc Res (2012) 1.57
Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ Res (2004) 1.57
Roles of endogenous monocyte chemoattractant protein-1 in ischemia-induced neovascularization. J Am Coll Cardiol (2004) 1.56
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens (2014) 1.56
Surgical management and outcomes in patients with Cushing disease with negative pituitary magnetic resonance imaging. World Neurosurg (2011) 1.55
Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J (2007) 1.55
Prediction of coronary artery disease in patients undergoing carotid endarterectomy. J Neurosurg (2005) 1.55
Dimethylarginine dimethylaminohydrolase prevents progression of renal dysfunction by inhibiting loss of peritubular capillaries and tubulointerstitial fibrosis in a rat model of chronic kidney disease. J Am Soc Nephrol (2007) 1.54
Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation (2004) 1.53
MARCO is the major binding receptor for unopsonized particles and bacteria on human alveolar macrophages. J Immunol (2005) 1.53
Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol (2007) 1.53
A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol (2007) 1.52
Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res (2009) 1.51
Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci (2013) 1.50
Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2004) 1.49
Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction. Cardiovasc Res (2004) 1.49
Role of CC chemokine receptor 2 in bone marrow cells in the recruitment of macrophages into obese adipose tissue. J Biol Chem (2008) 1.48
Cre-loxP-controlled periodic Aurora-A overexpression induces mitotic abnormalities and hyperplasia in mammary glands of mouse models. Oncogene (2004) 1.47
Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation (2004) 1.47
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. Cancer Sci (2011) 1.46
Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res (2002) 1.45
How to avoid development of AV block during RF ablation: anatomical and electrophysiological analyses at the time of AV node ablation. Pacing Clin Electrophysiol (2012) 1.45
Percutaneous coronary intervention plus medical therapy reduces the incidence of acute coronary syndrome more effectively than initial medical therapy only among patients with low-risk coronary artery disease a randomized, comparative, multicenter study. JACC Cardiovasc Interv (2008) 1.45
Impact of monocyte chemoattractant protein-1 deficiency on cerebral aneurysm formation. Stroke (2009) 1.45